Endocrinology Drugs Market Report 2026

The endocrinology drugs market size has grown marginally in recent years. It will grow from $26.2 billion in 2025 to $26.24 billion in 2026 at a compound annual growth rate (CAGR) of 0.1%. The growth in the historic period can be attributed to rising diabetes prevalence, increased thyroid disorder diagnosis, growth in hormone replacement usage, expansion of hospital pharmacies, improved endocrine awareness.

The endocrinology drugs market size is expected to see marginal growth in the next few years. It will grow to $26.42 billion in 2030 at a compound annual growth rate (CAGR) of 0.2%. The growth in the forecast period can be attributed to aging population, rising lifestyle-related disorders, growth in diabetes drug innovation, expansion of online pharmacies, increasing endocrine screening rates. Major trends in the forecast period include rising long-term management of chronic endocrine disorders, increasing use of combination hormonal therapies, growing demand for diabetes and thyroid disorder drugs, expansion of outpatient endocrine care, increased focus on hormone replacement therapies.

The increasing prevalence of endocrine diseases is anticipated to drive expansion in the endocrinology drugs market. Endocrine diseases involve disruptions to the endocrine system that lead to hormone production or regulation imbalances, disrupting normal bodily processes. This rise stems from factors like shifting lifestyles, a growing elderly population, and better diagnostic tools, all boosting the detection and occurrence of these disorders. Endocrinology drugs treat these conditions by normalizing hormone levels, correcting glandular issues, and reestablishing hormonal equilibrium to ease symptoms and enhance health results. For instance, in February 2025, the World Health Organization - a Switzerland-based UN agency dedicated to global public health - reported that polycystic ovary syndrome (PCOS) impacts 6 to 13% of women of reproductive age, with up to 70% of cases undiagnosed globally. Thus, the growing incidence of endocrine diseases is fueling demand in the endocrinology drugs market.

Major companies operating in the endocrinology drugs market are prioritizing product innovation and formulations like authorized generics of GLP-1 receptor agonists to boost patient access, cut treatment costs, and heighten competitiveness while upholding safety and efficacy. These tactics expand availability of essential diabetes and obesity therapies, fostering adherence to ongoing regimens - for instance, in June 2024, U.S.-based Teva Pharmaceuticals launched an authorized generic of Victoza (liraglutide) injection 1.8 mg in the United States, mirroring the branded product's formulation and benefits to offer clinicians and patients a budget-friendly option for managing type 2 diabetes and obesity, reflecting wider trends in generics that address surging global demand for such solutions.

In July 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Amolyt Pharma Inc. for an undisclosed sum. Through this acquisition, AstraZeneca seeks to bolster its portfolio in rare endocrine diseases by incorporating Amolyt Pharma's promising pipeline of late-stage therapies. Amolyt Pharma Inc. is a France-based pharmaceutical company focused on developing treatments for rare endocrine diseases.

Major companies operating in the endocrinology drugs market are Johnson & Johnson Inc., Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Novartis International AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Biocon Limited, Boehringer Ingelheim International GmbH, Mylan N.V., Sandoz International GmbH, Ipsen Pharma, Ferring Pharmaceuticals Inc., Endocrine Pharma Private Limited.

North America was the largest region in the endocrinology drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endocrinology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the endocrinology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted endocrinology drugs by increasing the cost of imported APIs and hormone formulations used in chronic disease management. These effects are most visible in diabetes and thyroid therapy segments, where demand volumes and supply reliability are critical. Regions such as North America and Asia Pacific have experienced higher input costs due to reliance on cross border pharmaceutical sourcing. Rising tariff related expenses have influenced pricing strategies, reimbursement discussions, and procurement planning across endocrinology treatments. At the same time, tariffs have encouraged local production, expanded domestic manufacturing capacity, and strengthened regional pharmaceutical supply chains over the long term.

The endocrinology drugs market research report is one of a series of new reports that provides endocrinology drugs market statistics, including endocrinology drugs industry global market size, regional shares, competitors with a endocrinology drugs market share, detailed endocrinology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the endocrinology drugs industry. This endocrinology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Endocrine drugs are pharmaceutical agents tailored to treat and control disorders of the endocrine system, encompassing glands like the thyroid, pancreas, and adrenals. They address conditions such as diabetes, thyroid issues, growth hormone shortages, and hormone imbalances, working to normalize hormone levels and enhance endocrine system performance.

Endocrinology drugs are primarily indicated for conditions like hyperthyroidism, hypothyroidism, diabetes, polycystic ovarian syndrome, growth hormone disorders, pituitary gland disorders, and more. Hyperthyroidism involves overproduction of thyroid hormones, resulting in symptoms including weight loss, fast heart rate, and nervousness. Key therapy categories encompass diabetes medications, drugs for thyroid hormone imbalances, human growth hormone, testosterone replacement therapy, and additional areas. These drugs reach patients via channels like hospital pharmacies, online pharmacies, and retail pharmacies, serving end users such as hospitals, ambulatory surgical centers, and others.

The endocrinology drugs market consists of sales of insulin analogs, antithyroid drugs, and anti-diabetic drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.